<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00243529</url>
  </required_header>
  <id_info>
    <org_study_id>2003-2917</org_study_id>
    <secondary_id>KWF 2003-2917</secondary_id>
    <nct_id>NCT00243529</nct_id>
  </id_info>
  <brief_title>Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients</brief_title>
  <official_title>In Vivo Responses of DC Vaccines Presenting HLA Class I and II Restricted Tumor Epitopes Either by Peptide-pulsing or mRNA Transfection in Melanoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dendritic cells (DCs)are the most potent antigen-presenting cells of the immune system, as
      such they are able to direct the immune system specifically against cancer cells. Currently
      DCs are used in clinical vaccination studies and immunological and clinical responses have
      been observed. For inducing anti-tumor immunity, the DCs have to be loaded with tumor antigen
      (i.e. molecular structures that are presented by the tumor, that are recognized by the immune
      system). Currently most studies use tumor peptides (small protein fragments) for this
      purpose. This approach has several disadvantages: only patients with a certain HLA-type can
      be treated and the immune response that is induced by the vaccine is limited to the used
      peptides. These disadvantages do not exist when the DCs present antigen which is endogenously
      processed, for example after RNA transfection. For this reason we investigate the
      immunogenicity of DCs that are pulsed with peptides or transfected with mRNA encoding
      melanoma associated antigens in stage III and IV melanoma patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune response</measure>
    <time_frame>first 10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>first 10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Melanoma Stage III or IV</condition>
  <arm_group>
    <arm_group_label>MHC Class I restricted epitopes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HLA-A2.1 patients are vaccinated with dendritic cells loaded with MHC Class I restricted epitopes of tumor antigens gp100 and tyrosinase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MHC Class I and II restricted epitopes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLA-A2.1 and HLA-DR4 patients are vaccinated with dendritic cells loaded with MHC Class I and II restricted epitopes of tumor antigens gp100 and tyrosinase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mRNA transfected DC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLA-A2.1 and/or HLA-DR4 patients are vaccinated with dendritic cells transfected with mRNA encoding tumor antigens gp100 and tyrosinase</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous dendritic cell vaccine</intervention_name>
    <arm_group_label>MHC Class I restricted epitopes</arm_group_label>
    <arm_group_label>MHC Class I and II restricted epitopes</arm_group_label>
    <arm_group_label>mRNA transfected DC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For both stage III and IV

          -  Histological proof of cutaneous melanoma

          -  Melanoma expressing both gp100 and tyrosinase, each in approximately 20% or more of
             cells by immunohistochemistry staining,

          -  HLA type A2 and/or A3, with known HLA-DR4 expression,

          -  WBC &gt; 3.0 x 109/l, lymphocytes &gt; 0.8 x 109/l, platelets &gt; 100 x 109/l, serum
             creatinine &lt; 150 μmol/l, serum bilirubin &lt; 25 μmol/l.

          -  Expected adequacy of follow-up,

          -  Written informed consent.

        For Stage III only

          -  Stage III melanoma according to the 2001 AJCC criteria.

          -  Start of treatment within 2 months of lymph node dissection for melanoma stage III

        For stage IV only

        -Stage IV melanoma according to the 2001 AJCC criteria. Limited tumor burden; LDH &lt; 2x
        upper limit of normal

        Exclusion Criteria:

        For both stage III and IV

          -  No autoimmune disorders, no concomitant use of immunosuppressive drugs,

          -  no serious concomitant disease, no serious active infections, no other malignancy in
             the past 5 years with the exception of curatively treated carcinoma in-situ of the
             cervix/squamous cell carcinoma of the skin,

          -  No known allergy to shell fish (contains KLH) are excluded.

          -  No pregnancy or lactation,

        For stage III only:

          -  No signs or symptoms of distant metastases as defined by normal history, physical
             examination, chest X-ray and serum LDH.

          -  No concomitant or previous systemic treatment for melanoma

        For stage IV only:

          -  No clinical signs of CNS metastases, in patients with a clinical suspicion of CNS
             metastases, a CT scan of the brain should be performed to exclude this.

          -  No prior chemotherapy, immunotherapy, or radiotherapy within three months before
             planned vaccination is allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. C.J.A. Punt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Nijmegen Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. G.J. Adema, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Nijmegen Medical Center/Nijmegen Center for Molecular Life Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>PO Box 9101</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.umcn.nl</url>
    <description>Home page of the Radboud University Nijmegen Medical Centre</description>
  </link>
  <link>
    <url>http://www.ncmls.eu/</url>
    <description>Website of the department of Tumor immunology of the Nijmegen Centre for Molecular Life Sciences of the Radboud University Nijmegen Medical Centre</description>
  </link>
  <reference>
    <citation>de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ, Ruiter DJ, Figdor CG, Punt CJ, Adema GJ. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol. 2005 Aug 20;23(24):5779-87.</citation>
    <PMID>16110035</PMID>
  </reference>
  <reference>
    <citation>Lesterhuis WJ, de Vries IJ, Adema GJ, Punt CJ. Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results. Ann Oncol. 2004;15 Suppl 4:iv145-51. Review.</citation>
    <PMID>15477299</PMID>
  </reference>
  <reference>
    <citation>Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004 May;10(5):475-80. Review.</citation>
    <PMID>15122249</PMID>
  </reference>
  <reference>
    <citation>de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 2003 Nov 1;9(14):5091-100.</citation>
    <PMID>14613986</PMID>
  </reference>
  <reference>
    <citation>De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN, Strijk SP, Ruers TJ, Boerman OC, Oyen WJ, Adema GJ, Punt CJ, Figdor CG. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 2003 Jan 1;63(1):12-7.</citation>
    <PMID>12517769</PMID>
  </reference>
  <reference>
    <citation>de Vries IJ, Eggert AA, Scharenborg NM, Vissers JL, Lesterhuis WJ, Boerman OC, Punt CJ, Adema GJ, Figdor CG. Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother. 2002 Sep-Oct;25(5):429-38.</citation>
    <PMID>12218781</PMID>
  </reference>
  <reference>
    <citation>Adema GJ, de Vries IJ, Punt CJ, Figdor CG. Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol. 2005 Apr;17(2):170-4. Review.</citation>
    <PMID>15766677</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2005</study_first_submitted>
  <study_first_submitted_qc>October 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2005</study_first_posted>
  <last_update_submitted>September 28, 2009</last_update_submitted>
  <last_update_submitted_qc>September 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. C.J.A. Punt, MD, PhD</name_title>
    <organization>Radboud University Nijmegen Medical Centre</organization>
  </responsible_party>
  <keyword>Dendritic cells</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>RNA</keyword>
  <keyword>Peptides</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

